Roche Holding is launching the VENTANA HER2 Dual ISH DNA Probe Cocktail assay, a companion diagnostic test designed to identify HER2-positive breast or gastric cancer patients who can benefit from Herceptin therapy, in Europe, Africa, Asia Pacific, Middle East and Latin America. The company said it will seek approval for use in the US from the FDA.
Roche launches companion Dx for breast, gastric cancer drug
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.